A physician gives Durvalumab via an intravenous (IV) infusion. The following is what you need to learn about taking it:

• Given in a Hospital or Clinic Setting: Durvalumab is given IV, probably in a hospital or clinic setting. The infusion takes about 60 minutes, and your health care provider will monitor for side effects after the infusion and while on the infusion. 
• Routine Visits: You will be required to report for routine visits so that you can take the medicine. Your doctor will determine how often how often the infusions should be administered to you based on your treatment regimen and the extent to which your body is able to absorb the drug.
• Precautions: Inform your doctor about other drugs you may be using, including over-the-counter drugs, vitamins, and past cancer therapy, before undergoing the treatment.

• Durvalumab acts by blocking and targeting the PD-L1 (Programmed Death-Ligand 1) protein. The protein naturally occurs on cancer cell surfaces and is uniquely responsible for assisting immune evasion by cancer cells. In being anchored to its receptor (PD-1) on immune cells, PD-L1 essentially silences the immune response, and thus the cancer cells drift by, unsuspecting and undamaged.
• Durvalumab is a PD-L1 inhibitor and functions by blocking PD-L1 and hindering such interaction. Through this, immune cells (T-cells) can easily identify and destroy cancer cells. This makes it possible for the body’s immune system to target the cancer cells to be destroyed effectively, which reduces or shrinks the tumor’s growth. 

As with any drug, Durvalumab can have side effects. Side effects are generally controlled, but some are serious. Common and serious side effects of Durvalumab are:

Common Side Effects:

• Fatigue (tiredness)
• Nausea
• Loss of appetite
• Shortness of breath
• Cough

Serious Side Effects:

• Immune System Side Effects: Being an immunostimulatory agent, that is, actually stimulating the immune system, Durvalumab can cause immune-related side effects of organ inflammation. It can cause inflammation of the lungs, liver, intestines, kidneys, or any other organ. These can occur in the form of fever, cough, chest pain, diarrhea, or jaundice.
• Severe Allergic Reactions: Although uncommon, some individuals can develop allergic reactions such as shortness of breath, swelling, or rash.
• Infections: Hyperimmune response could lead to infection, such as pneumonia, urinary tract infection, or other bacterial or viral infection.

If any of the severe side effects occur, such as shortness of breath, worsening weakness, or worsening cough, call your physician immediately.

Before initiating Durvalumab, consider the following:

• Immune Side Effects: Durvalumab can stimulate the immune system, triggering inflammation or autoimmune effects on the normal tissues. This can contribute to severe side effects, including inflammation of the organs. Ensure that your doctor is informed if you have a history of autoimmune disease.
• Risk of Infection: Durvalumab has the potential to increase the risk of infection with its immunologic action. Infection control practices should be followed by the patient, and any sign of infection should be reported immediately
• Pregnancy and Lactation: Durvalumab should not be administered during pregnancy as it is not safe for a fetus. If pregnant, become pregnant, or are breastfeeding, inform your doctor before treatment is started
• Pre-existing Medical Conditions: Inform your doctor of any pre-existing history of lung disease, liver disease, or other chronic illness. Durvalumab may be altered based on your medical history.

• Immune System Interactions: Since Durvalumab is an immunotherapy that stimulates the immune system, when used with other immunotherapies, it can cause overstimulation of the immune system with resultant inflammation and autoimmune effects.
• Other Cancer Therapies: If you are on chemotherapy or radiation, make sure to discuss with your physician how these will interact with Durvalumab. Combined therapies may possibly enhance the therapy either more or less effectively and cause extra side effects.

Durvalumab is often administered via IV infusion. The standard dose is:

• Non-Small Cell Lung Cancer: 10 mg/kg body weight every 2 weeks.
• Urothelial Carcinoma: 10 mg/kg every 2 weeks (when administered in combination with other drugs, the dosing regimen and quantity may differ).
• Your physician will decide on the precise dosage and course of treatment based on your individual circumstances and how you are responding to the treatment.

Durvalumab is a prescription medication, and you will have to obtain a physician to prescribe the drug for you. The drug must be administered only by trained doctors or other medical experts in a physician’s clinic or hospital since the infusion will need close monitoring for side effects. You can get Durvalumab only upon a doctor’s prescription, and only according to the treatment regimen your doctor or oncologist establishes should you consume it.

1. What is Durvalumab?
   Durvalumab is an immunotherapy drug used to treat certain types of cancer by helping the immune system detect and fight cancer cells.

2. Which cancers is Durvalumab approved to treat?
   It is used in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and bladder cancer (urothelial carcinoma).

3. How does Durvalumab work?
   It blocks the PD-L1 protein, allowing T-cells to better recognize and attack cancer cells.

4. Is Durvalumab a chemotherapy drug?
   No, it is an immunotherapy drug, not a traditional chemotherapy.

5. How is Durvalumab given?
   It is administered by intravenous (IV) infusion, usually every 2 to 4 weeks.

6. How long does each infusion of Durvalumab take?
   Typically 60 minutes for each IV infusion.

7. Can Durvalumab be used in combination with other treatments?
   Yes, it is sometimes combined with chemotherapy or radiation depending on the cancer type.

8. What are the common side effects of Durvalumab?
   Fatigue, cough, diarrhea, skin rash, decreased appetite, and shortness of breath.

9. Are there serious risks with Durvalumab?
   Yes, it may cause immune-related side effects affecting the lungs, liver, thyroid, or other organs.

10. Is Durvalumab safe for all patients?
    It may not be suitable for patients with autoimmune diseases or certain medical conditions.

11. Can Durvalumab be used in children?
    It is generally approved for adults, not pediatric use.

12. How long does treatment with Durvalumab usually last?
    Duration varies but often continues up to 12 months or until disease progression.

13. Does Durvalumab affect fertility or pregnancy?
    It may harm an unborn baby; contraception is recommended during and after treatment.

14. Can breastfeeding patients take Durvalumab?
    No, breastfeeding is not recommended during treatment.

15. How effective is Durvalumab in treating lung cancer?
    Clinical studies show improved survival rates in patients with NSCLC and SCLC.

16. Does Durvalumab require hospital visits?
    Yes, since it is given via IV infusion under medical supervision.

17. Is Durvalumab considered a targeted therapy?
    It is classified as an immune checkpoint inhibitor, a type of targeted immunotherapy.

18. How is the dose of Durvalumab determined?
    It is based on body weight or fixed dosing depending on the treatment plan.

19. Does Durvalumab have interactions with other medicines?
    Yes, especially with immune-suppressing drugs; always consult your doctor.

20. When should Durvalumab treatment be stopped?
    If cancer progresses, severe side effects occur, or as recommended by the oncologist.